Eyenovia to Report First Quarter 2021 Results on Wednesday, May 12
05 mai 2021 08h00 HE
|
Eyenovia, Inc.
NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array...
Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
25 mars 2021 16h05 HE
|
Eyenovia, Inc.
Announces MydCombi expected PDUFA date of October 28, 2021 Completes patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; topline data on track for Q2 ...
Eyenovia to Report Fourth Quarter and Full Year 2020 Results on Thursday, March 25
18 mars 2021 08h00 HE
|
Eyenovia, Inc.
NEW YORK, March 18, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose...
Eyenovia to Participate in the 33rd Annual Roth Conference
10 mars 2021 08h00 HE
|
Eyenovia, Inc.
NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary...
Eyenovia to Host Key Opinion Leader Webinar on Presbyopia
16 févr. 2021 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia to Participate in Presbyopia Panel Discussion at the LifeSci Partners 10th Annual Corporate Access Event
06 janv. 2021 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Reports Third Quarter 2020 Financial Results
10 nov. 2020 16h06 HE
|
Eyenovia, Inc.
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10
05 nov. 2020 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million
13 oct. 2020 07h00 HE
|
Eyenovia, Inc.
Company reaffirms near term milestones for the Mydcombi™ (MicroStat) NDA and the MicroLine presbyopia program Phase III results Call scheduled for today, Tuesday, October 13 at 4:30pm ET ...
Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference
09 sept. 2020 08h30 HE
|
Eyenovia, Inc.
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...